{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:12Z","timestamp":1790052972819,"version":"4.0.1"},"reference-count":28,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Neurodegener Dis"],"DOI":"10.62347\/soge3962","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:49:15Z","timestamp":1740977355000},"page":"34-41","source":"Crossref","is-referenced-by-count":5,"title":["The role of nuclear medicine in neurodegenerative diseases: a narrative review"],"prefix":"10.62347","volume":"14","author":[{"given":"Farshad","family":"Riahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3390\/ijms24043321","article-title":"Review of technological challenges in personalised medicine and early diagnosis of neurodegenerative disorders","volume":"24","author":"Dom&#xED","year":"2023","unstructured":"Domínguez-Fernández C, Egiguren-Ortiz J, Razquin J, Gómez-Galán M, De las Heras-García L, Paredes-Rodríguez E, Astigarraga E, Miguélez C and Barreda-Gómez G. Review of technological challenges in personalised medicine and early diagnosis of neurodegenerative disorders. Int J Mol Sci 2023; 24: 3321.","journal-title":"Int J Mol Sci"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/19336896.2019.1706703","article-title":"An enigmatic case of cortical anopsia: antemortem diagnosis of a 14-3-3 negative heidenhain-variant MM1-sCJD","volume":"14","author":"Obergassel","year":"2020","unstructured":"Obergassel J, Lohmann L, Meuth SG, Wiendl H, Grauer O and Nelke C. An enigmatic case of cortical anopsia: antemortem diagnosis of a 14-3-3 negative heidenhain-variant MM1-sCJD. Prion 2020; 14: 24-28.","journal-title":"Prion"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.31083\/j.jin2102073","article-title":"Infectious agents and Alzheimer’s disease","volume":"21","author":"Piekut","year":"2022","unstructured":"Piekut T, Hurła M, Banaszek N, Szejn P, Dorszewska J, Kozubski W and Prendecki M. Infectious agents and Alzheimer’s disease. J Integr Neurosci 2022; 21: 73.","journal-title":"J Integr Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"20200095","DOI":"10.1259\/bjr.20200095","article-title":"Nuclear medicine and molecular imaging advances in the 21st century","volume":"93","author":"Vaz","year":"2020","unstructured":"Vaz SC, Oliveira F, Herrmann K and Veit-Haibach P. Nuclear medicine and molecular imaging advances in the 21st century. Br J Radiol 2020; 93: 20200095.","journal-title":"Br J Radiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2967\/jnumed.123.266463","article-title":"Evaluation of neurodegenerative disorders with Amyloid-β, Tau, and dopaminergic PET imaging: interpretation pitfalls","volume":"65","author":"BJ","year":"2024","unstructured":"Burkett BJ, Johnson DR and Lowe VJ. Evaluation of neurodegenerative disorders with Amyloid-β, Tau, and dopaminergic PET imaging: interpretation pitfalls. J Nucl Med 2024; 65: 829-837.","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.62347\/QPAG5693","article-title":"Extracellular vesicles and their therapeutic applications: a review article (part1)","volume":"16","author":"Rafieezadeh","year":"2024","unstructured":"Rafieezadeh D and Rafieezadeh A. Extracellular vesicles and their therapeutic applications: a review article (part1). Int J Physiol Pathophysiol Pharmacol 2024; 16: 1-9.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.62347\/TUVQ7468","article-title":"Marine bioactive peptides with anticancer potential, a narrative review","volume":"15","author":"Rafieezadeh","year":"2024","unstructured":"Rafieezadeh D and Esfandyari G. Marine bioactive peptides with anticancer potential, a narrative review. Int J Biochem Mol Biol 2024; 15: 118-126.","journal-title":"Int J Biochem Mol Biol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.62347\/JGQA3746","article-title":"Exploring the seas for cancer cures: the promise of marine-derived bioactive peptide","volume":"15","author":"Rafieezadeh","year":"2024","unstructured":"Rafieezadeh D and Abbaspour M. Exploring the seas for cancer cures: the promise of marine-derived bioactive peptide. Int J Biochem Mol Biol 2024; 15: 100-106.","journal-title":"Int J Biochem Mol Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.62347\/AUPQ6330","article-title":"Extracellular vesicles and their therapeutic applications: a review article (part 2)","volume":"16","author":"Rafieezadeh","year":"2024","unstructured":"Rafieezadeh D. Extracellular vesicles and their therapeutic applications: a review article (part 2). Int J Physiol Pathophysiol Pharmacol 2024; 16: 81-88.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Young PN, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, Venkataraman AV, Lissaman R, Jiménez D and Betts MJ. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther 2020; 12: 1-17.","DOI":"10.1186\/s13195-020-00612-7"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/pharmaceutics13101619","article-title":"D-peptide-based probe for CXCR4-targeted molecular imaging and radionuclide therapy","volume":"13","author":"Luyten","year":"2021","unstructured":"Luyten K, Van Loy T, Cawthorne C, Deroose CM, Schols D, Bormans G and Cleeren F. D-peptide-based probe for CXCR4-targeted molecular imaging and radionuclide therapy. Pharmaceutics 2021; 13: 1619.","journal-title":"Pharmaceutics"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M and Graham MM. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med 2020; 61 Suppl 2: 263S-272S.","DOI":"10.2967\/jnumed.120.254532"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40001-023-01627-0","article-title":"Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation","volume":"29","author":"Dhoundiyal","year":"2024","unstructured":"Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, Mishra N and Taghizadeh-Hesary F. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res 2024; 29: 26.","journal-title":"Eur J Med Res"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Tiepolt S, Meyer PM, Patt M, Deuther-Conrad W, Hesse S, Barthel H and Sabri O. PET imaging of cholinergic neurotransmission in neurodegenerative disorders. J Nucl Med 2022; 63 Suppl 1: 33S-44S.","DOI":"10.2967\/jnumed.121.263198"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/brain\/awy099","article-title":"Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia","volume":"141","author":"Sabri","year":"2018","unstructured":"Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S, Becker GA, Rullmann M, Patt M, Luthardt J and Wagenknecht G. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia. Brain 2018; 141: 1840-1854.","journal-title":"Brain"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Chapleau M, Iaccarino L, Soleimani-Meigooni D and Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med 2022; 63 Suppl 1: 13S-19S.","DOI":"10.2967\/jnumed.121.263195"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s13311-021-01030-9","article-title":"Uses of human MR and PET imaging in research of neurodegenerative brain diseases","volume":"18","author":"Schwarz","year":"2021","unstructured":"Schwarz CG. Uses of human MR and PET imaging in research of neurodegenerative brain diseases. Neurotherapeutics 2021; 18: 661-672.","journal-title":"Neurotherapeutics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3174\/ajnr.A7079","article-title":"Complete evaluation of dementia: PET and MRI correlation and diagnosis for the neuroradiologist","volume":"42","author":"Oldan","year":"2021","unstructured":"Oldan J, Jewells V, Pieper B and Wong T. Complete evaluation of dementia: PET and MRI correlation and diagnosis for the neuroradiologist. Am J Neuroradiol 2021; 42: 998-1007.","journal-title":"Am J Neuroradiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fncel.2020.00075","article-title":"Gliosis and neurodegenerative diseases: the role of PET and MR imaging","volume":"14","author":"Cavaliere","year":"2020","unstructured":"Cavaliere C, Tramontano L, Fiorenza D, Alfano V, Aiello M and Salvatore M. Gliosis and neurodegenerative diseases: the role of PET and MR imaging. Front Cell Neurosci 2020; 14: 75.","journal-title":"Front Cell Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-019-0070-7","article-title":"Current radiotracers to image neurodegenerative diseases","volume":"4","author":"Tiepolt","year":"2019","unstructured":"Tiepolt S, Patt M, Aghakhanyan G, Meyer PM, Hesse S, Barthel H and Sabri O. Current radiotracers to image neurodegenerative diseases. EJNMMI Radiopharm Chem 2019; 4: 1-23.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.31083\/j.jin2206172","article-title":"Positron emission tomography molecular imaging of the major neurodegenerative disorders: overview and pictorial essay, from a nuclear medicine center’s perspective","volume":"22","author":"Calabria","year":"2023","unstructured":"Calabria F, Leporace M, Cimini A, Ricci M, Travascio L and Bagnato A. Positron emission tomography molecular imaging of the major neurodegenerative disorders: overview and pictorial essay, from a nuclear medicine center’s perspective. J Integr Neurosci 2023; 22: 172.","journal-title":"J Integr Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms23095023","article-title":"Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade","volume":"23","author":"Crisan","year":"2022","unstructured":"Crisan G, Moldovean-Cioroianu NS, Timaru DG, Andries G, Căinap C and Chis V. Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int J Mol Sci 2022; 23: 5023.","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2967\/jnmt.118.224022","article-title":"An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals","volume":"47","author":"Mantel","year":"2019","unstructured":"Mantel E and Williams J. An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals. J Nucl Med Technol 2019; 47: 203-209.","journal-title":"J Nucl Med Technol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-020-00094-w","article-title":"Imaging using radiolabelled targeted proteins: Radioimmunodetection and beyond","volume":"5","author":"Garousi","year":"2020","unstructured":"Garousi J, Orlova A, Frejd FY and Tolmachev V. Imaging using radiolabelled targeted proteins: Radioimmunodetection and beyond. EJNMMI Radiopharm Chem 2020; 5: 1-26.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"ref24","unstructured":"Szymański P, Markowicz M, Janik A, Ciesielski M and Mikiciuk-Olasik E. Neuroimaging diagnosis in neurodegenerative diseases. Nucl Med Rev 2010; 13: 23-31."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia","volume":"142","author":"Pontecorvo","year":"2019","unstructured":"Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, Salloway S, Doraiswamy PM, Southekal S and Arora AK. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain 2019; 142: 1723-1735.","journal-title":"Brain"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"787404","DOI":"10.3389\/fnins.2022.787404","article-title":"PET imaging of synaptic density: challenges and opportunities of synaptic vesicle glycoprotein 2A PET in small animal imaging","volume":"16","author":"Toyonaga","year":"2022","unstructured":"Toyonaga T, Fesharaki-Zadeh A, Strittmatter SM, Carson RE and Cai Z. PET imaging of synaptic density: challenges and opportunities of synaptic vesicle glycoprotein 2A PET in small animal imaging. Front Neurosci 2022; 16: 787404.","journal-title":"Front Neurosci"},{"key":"ref27","unstructured":"Huang WS, Lin SZ, Lin JC, Wey SP, Ting G and Liu RS. Evaluation of early-stage Parkinson’s disease with 99mTc-TRODAT-1 imaging. J Nucl Med 2001; 42: 1303-1308."}],"container-title":["American Journal of Neurodegenerative Disease"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajnd\/14\/1\/ajnd0161598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:51Z","timestamp":1766023071000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajnd\/14\/1\/ajnd0161598.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/soge3962","relation":{},"ISSN":["2165-591X"],"issn-type":[{"value":"2165-591X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}